+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-06-19Number of Pages: 99

Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and Human Insulin) - Industry Analysis, Size, Share, Growth, Trends and Forecast (Value and Volume) 2013 - 2019

Diabetes is a chronic metabolic disorder wherein the body is either unable to produce insulin (glucose digesting hormone) or unable to utilize the produced insulin to metabolize blood glucose. This condition results in increased blood glucose level, which leads to various chronic and life-threatening diseases. Insulin is a hormone secreted by β-cells of pancreas in order to metabolize the blood sugar. The insulin market is a rapidly growing market. Demand for premixed and long-acting insulin derivatives is growing rapidly due to rising incidences of type 1 diabetes. This report focuses on identifying the current scenario as well as the future market potential for insulin globally. Additionally, the insulin market in China is also analyzed and studied thoroughly. The insulin market is segmented based on two important parameters: by mode of action and by source. By mode of action, the market (global and China) is categorized as rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Furthermore, by source, the market is categorized as human insulin and modern insulin.

 

Long-acting insulin derivatives is projected to be the fastest growing segment, expanding at a CAGR of 8.7% during the forecast period from 2013 to 2019. According to the World Health Organization (WHO), more than 366 million people worldwide were diagnosed with diabetes in 2011 and an additional 280 million are expected to be diagnosed over the next 20 years. Majority of these patients are likely to be from emerging markets such as China and India. 

 

Rising demand for long-acting insulin derivatives is attributed to advantages such as reduced number of doses compared to other derivatives. Moreover, strong pipeline, lack of stringent regulations on price capping and high entry barriers for biosimilar manufacturers are other important growth drivers in the market. The market for modern insulin is also expected to increase during the forecast period from 2013 to 2019 due to various factors such as ease-of-administration and higher efficacy.

 

In China, premixed insulin derivatives accounted for more than 50% of the market in 2012. Large population of type 1 diabetes patients and rising preference for insulin as diabetes treatment (both type 1 and type 2) are some of the factors contributing to the growth of the insulin market in China. Moreover, improving medical infrastructure, changing lifestyle, increased consumption of fast food and changing dietary habits are some of the factors expected to drive the insulin market in China.

 

The global insulin market is highly consolidated and dominated by few market players such as Eli Lilly and Company, Sanofi, and Novo Nordisk A/S. Moreover, these players account for more than 80% of the total insulin market in China. Domestic players such as Shanghai Fosun Pharmaceutical Co., Ltd. and Tonghua Dongbao hold a small share in the Chinese market.

 

 

Chapter 1 Preface

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

      1.3.1 Sources

               1.3.1.1 Secondary Research

               1.3.1.2 Primary Research

      1.3.2 Assumptions

 

Chapter 2 Executive Summary

2.1 Market Snapshot: Global Insulin Market (2012 & 2019)

2.2 Market Snapshot: China Insulin Market (2012 & 2019)

 

Chapter 3 Market Overview

3.1 Overview

3.2 Market Drivers

      3.2.1 Global rise in diabetic population

      3.2.2 No strict regulations on price capping

      3.2.3 High entry barriers for biosimilar manufacturers

3.3 Market Restraints

      3.3.1 Growing acceptance of SGLT2 and GLP-1 agents among type 2 diabetes patients will delay the shift to insulin therapy

      3.3.2 High cost of products restrains the uptake of insulin in emerging markets

3.4 Market Opportunities

      3.4.1 Development of combination products

      3.4.2 Strong Pipeline

3.5 Value Chain: Global Insulin Market

3.6 Porter’s Five Force Analysis of the Global Insulin Market

      3.6.1 Bargaining power of suppliers

      3.6.2 Bargaining power of buyers

      3.6.3 Threat of substitutes

      3.6.4 Threat of new entrants

      3.6.5 Competitive rivalry

3.7 Market Attractiveness Analysis: Global Insulin Market, by Mode of Action

 

Chapter 4 Global Insulin Market, by Mode of Action

4.1 Overview

      4.1.1 Characteristics of type of Insulin

      4.1.2 Global Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million)

      4.1.3 Global Insulin Market Volume, by Mode of Action, 2011 – 2019 (tMU)

      4.1.4 Comparative Analysis: Global Insulin Market Revenue, by Mode of Action, 2012 & 2019 (Value %)

4.2 Short-Acting Insulin

      4.2.1 Global Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

      4.2.2 Global Short-Acting Insulin Market Volume, 2011 – 2019 (tMU)

4.3 Rapid-Acting Insulin

      4.3.1 Global Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

      4.3.2 Global Rapid-Acting Insulin Market Volume, 2011 – 2019 (tMU)

      4.3.3 Pipeline Analysis

               4.3.3.1 Afrezza

                          4.3.3.1.1 Global Afrezza Market Revenue, 2015 – 2019 (USD Million)

               4.3.3.2 NN1218 (FIAsp)

                          4.3.3.2.1 Global NN1218 Market, 2016 – 2019 (USD Million)

4.4 Long-Acting Insulin

      4.4.1 Global Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

      4.4.2 Global Long-Acting Insulin Market Volume, 2011 – 2019 (tMU)

      4.4.3 Pipeline Analysis

               4.4.3.1 LY2605541(Novel Basal Insulin Analog)

                          4.4.3.1.1 Global LY2605541 Market Revenue, 2015 – 2019 (USD Million)

               4.4.3.2 LY2963016 (Long acting basal insulin)

                          4.4.3.2.1 Global LY2963016 Market Revenue, 2014 – 2019 (USD Million)

               4.4.3.3 MK-1293 (Sustained release insulin analog)

                          4.4.3.3.1 Global MK-1293 Market Revenue, 2016 – 2019 (USD Million)

               4.4.3.4 U-300 (Toujeo)

                          4.4.3.4.1 Global U-300 Market Revenue, 2015 – 2019 (USD Million)

               4.4.3.5 IDegLira (Xultophy)

                          4.4.3.5.1 Global IDegLira Market Revenue, 2014 – 2019 (USD Million)

4.5 Intermediate-Acting Insulin

      4.5.1 Global Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

      4.5.2 Global Intermediate-Acting Insulin Market Volume, 2011 – 2019 (tMU)

4.6 Premixed Insulin

      4.6.1 Global Premixed Insulin Market Revenue, 2011 – 2019 (USD Million)

      4.6.2 Global Premixed Insulin Market Volume, 2011 – 2019 (tMU)

 

Chapter 5 China Insulin Market, by Mode of Action

5.1 Overview

5.2 Breakdown of insulin-dependent population in China (2009)

      5.2.1 China Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million)

      5.2.2 China Insulin Market Volume, by Mode of Action, 2011 – 2019 (tMU)

5.3 Short-Acting Insulin

      5.3.1 China Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

      5.3.2 China Short-Acting Insulin Market Volume, 2011 – 2019 (tMU)

5.4 Rapid-Acting Insulin

      5.4.1 China Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

      5.4.2 China Rapid-Acting Insulin Market Volume, 2011 – 2019 (tMU)

5.5 Long-Acting Insulin

      5.5.1 China Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

      5.5.2 China Long-Acting Insulin Market Volume, 2011 – 2019 (tMU)

5.6 Intermediate-Acting Insulin

      5.6.1 China Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

      5.6.2 China Intermediate -Acting Insulin Market Volume, 2011 – 2019 (tMU)

5.7 Premixed Insulin

      5.7.1 China Premixed Insulin Market Revenue, 2011 – 2019 (USD Million)

      5.7.2 China Premixed Insulin Market Volume, 2011 – 2019 (tMU)

 

Chapter 6 Global Insulin Market, by Source

6.1 Overview

      6.1.1 Global Insulin Market Revenue, by Source, 2011 – 2019 (USD Million)

      6.1.2 Global Insulin Market Volume, by Source, 2011 – 2019 (tMU)

6.2 Human Insulin

      6.2.1 Global Human Insulin Market Revenue, 2011 – 2019 (USD Million)

      6.2.2 Global Human Insulin Market Volume, 2011 – 2019 (tMU)

6.3 Modern Insulin

      6.3.1 Global Modern Insulin Market Revenue, 2011 – 2019 (USD Million)

      6.3.2 Global Modern Insulin Market Volume, 2011 – 2019 (tMU)

 

Chapter 7 China Insulin Market, by Source

7.1 Overview

      7.1.1 China Insulin Market Revenue, by Source, 2011 – 2019 (USD Million)

      7.1.2 China Insulin Market Volume, by Source, 2011 – 2019 (tMU)

7.2 Human Insulin

      7.2.1 China Human Insulin Market Revenue, 2011 – 2019 (USD Million)

      7.2.2 China Human Insulin Market Volume, 2011 – 2019 (tMU)

7.3 Modern Insulin

      7.3.1 China Modern Insulin Market Revenue, 2011 – 2019 (USD Million)

      7.3.2 China Modern Insulin Market Volume, 2011 – 2019 (tMU)

 

Chapter 8 Competitive Landscape

8.1 Market Share Analysis: Global Insulin Market, 2012 (%)

      8.1.1 Global Insulin Market Share Analysis, by Key Players, 2012 (%)

8.2 Market Share Analysis: China Insulin Market, 2012 (%)

      8.2.1 China Insulin Market Share Analysis, by Key Players, 2012 (%)

 

Chapter 9 Recommendations

9.1 Development of formulations that can be administered by different routes

9.2 Development of combination formulations

9.3 Overcoming technical incompatibilities

9.4 Focus on emerging markets

 

Chapter 10 Company Profiles

10.1 Eli Lilly and Company

      10.1.1 Company Overview

      10.1.2 Financial Overview

      10.1.3 Product Portfolio

      10.1.4 Business Strategies

      10.1.5 Recent Developments

10.2 Novo Nordisk A/S

      10.2.1 Company Overview

      10.2.2 Financial Overview

      10.2.3 Product Portfolio

      10.2.4 Business Strategies

      10.2.5 Recent Developments

10.3 Sanofi

      10.3.1 Company Overview

      10.3.2 Financial Overview

      10.3.3 Product Portfolio

      10.3.4 Business Strategies

      10.3.5 Recent Developments

10.4 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

      10.4.1 Company Overview

      10.4.2 Financial Overview

      10.4.3 Business Overview

      10.4.4 Recent Developments

List of Figures

 

FIG. 1 Insulin: Market Segmentation

FIG. 2 Global Insulin Market Revenue, by Mode of Action, 2012 (USD Million)

FIG. 3 China Insulin Market Revenue, by Mode of Action, 2012 (USD Million)

FIG. 4 Value Chain: Global Insulin Market

FIG. 5 Porter’s Five Forces Analysis: Global Insulin Market

FIG. 6 Market Attractiveness Analysis: Global Insulin Market, by Mode of Action

FIG. 7 Comparative Analysis: Global Insulin Market Revenue, by Mode of Action 2012 & 2019 (Value %)

FIG. 8 Global Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 9 Global Short-Acting Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 10 Global Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 11 Global Rapid-Acting Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 12 Global Afrezza Market Revenue, 2015 – 2019 (USD Million)

FIG. 13 Global NN1218 Market Revenue, 2016 – 2019 (USD Million)

FIG. 14 Global Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 15 Global Long-Acting Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 16 Global LY2605541 Market Revenue, 2015 – 2019 (USD Million)

FIG. 17 Global LY2963016 Market Revenue, 2014 – 2019 (USD Million)

FIG. 18 Global MK-1293 Market Revenue , 2016 – 2019 (USD Million)

FIG. 19 Global U-300 Market Revenue, 2015 – 2019 (USD Million)

FIG. 20 Global IDegLira Market Revenue, 2014– 2019 (USD Million)

FIG. 21 Global Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 22 Global Intermediate-Acting Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 23 Global Premixed Market Revenue, 2011 – 2019 (USD Million)

FIG. 24 Global Premixed Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 25 Breakdown of insulin-dependent population in China (2009)

FIG. 26 China Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 27 China Short-Acting Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 28 China Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 29 China Rapid-Acting Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 30 China Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 31 China Long-Acting Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 32 China Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 33 China Intermediate-Acting Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 34 China Premixed Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 35 China Premixed Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 36 Global Human Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 37 Global Human Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 38 Global Modern Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 39 Global Modern Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 40 China Human Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 41 China Human Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 42 China Modern Insulin Market Revenue, 2011 – 2019 (USD Million)

FIG. 43 China Modern Insulin Market Volume, 2011 – 2019 (tMU)

FIG. 44 Global Insulin Market Share Analysis, by Key Players, 2012 (%)

FIG. 45 Global Insulin Market Share Analysis, by Key Players, 2012 (%)

FIG. 46 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 47 Novo Nordisk A/S.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 48 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 49 Shanghai Fosun Pharmaceutical Co., Ltd.: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

 

TABLE 1 Market Snapshot: Global Insulin Market (2012 & 2019)

TABLE 2 Market Snapshot: China Insulin Market (2012 & 2019)

TABLE 3 Global Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million)

TABLE 4 Global Insulin Market Volume, by Mode of Action, 2011 – 2019 (tMU)

TABLE 5 China Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million)

TABLE 6 China Insulin Market Volume, by Mode of Action, 2011 – 2019 (tMU)

TABLE 7 Global Insulin Market Revenue, by Source, 2011 – 2019 (USD Million)

TABLE 8 Global Insulin Market Volume, by Source, 2011 – 2019 (tMU)

TABLE 9 China Insulin Market Revenue, by Source, 2011 – 2019 (USD Million)

TABLE 10 China Insulin Market Volume, by Source, 2011 – 2019 (tMU)

According to recently published data by the WHO, there are about 150 mn people with diabetes mellitus across the world. The organization attributes this alarming figure to the rising ageing population, genetic predispositions, and growing prevalence of a sedentary lifestyles. If these factors continue to have a steady impact, the current figure is expected to double by 2025.

The expert industry analysts have suggested that the growing population suffering from type 1 diabetes and increasing usage or prescription of insulin for diabetics are the two main factors bolstering the global and China insulin market. In addition, the growth of the insulin market will also be augmented as lifestyles change, medical infrastructures improve, and dietary habits shift towards fast food, becoming the precursor for diabetes in many cases, around the world. The research report analyzes the market with the help of SWOT analysis and Porter’s five forces analysis. With the former, it sheds light on the strengths, weaknesses, opportunities, and threats of the market, while the latter is used for determining the threat of new entrants, threat of substitute products or services, bargaining power of customers (buyers), bargaining power of suppliers, and intensity of competitive rivalry.

Overview

The research report states that the global and China insulin market is expected to grow at a CAGR of 6.10% between 2013 and 2019 to reach US$32.2 bn by the end of 2019, from US$19.9 bn in 2012. The global and China insulin market is segmented on the basis of mode of action and source. The modes of action seen in the insulin market are rapid-acting, long-acting, short-acting, intermediate-acting, and premixed. On the other hand, the sources of insulin are human insulin and modern insulin.

Amongst the types of insulin, the long-lasting insulin segment is expected to grow at a CAGR of 8.70% in the forecast period. This mode of action for managing sugar levels will be popular amongst insulin-dependent diabetics, as only a small dosage is required to bring down blood glucose. Additionally, relatively relaxed regulations regarding the pricing of long-lasting insulin and availability of a wide range of products will also foster the growth of this segment in the overall insulin market.

In 2012, the rapid-acting insulin segment was at the second position in the overall market. In the same period, the premixed insulin segment held a market share of over 50% in the global and China insulin market. In the foreseeable future, intermediate-acting and short-acting insulin are expected to lose ground, as diabetics are shifting preferences and neither of these types of insulin are supported by adequate research and development channels.

Companies Mentioned in the Global and China Insulin Market are:

Some of the important players in the global and China insulin market are Novo Nordisk A/S, Sanofi, and Eli Lilly and Company.

Global and China insulin market is segmented on the basis of geography as follows:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top